Residency · Residency · Urology

Prostate Biopsy: Systematic vs. MRI-Fusion Approaches

Overview

Prostate biopsy techniques primarily include transrectal and transperineal approaches, each with distinct advantages and limitations. The use of multiparametric MRI (mpMRI) and PI-RADS scoring has revolutionized lesion detection, guiding targeted biopsies. Fusion biopsy methods can be cognitive, relying on the operator’s mental registration of MRI findings with ultrasound images, or software-assisted, which co-register MRI and real-time ultrasound images for precise targeting. Infection prophylaxis strategies have evolved, especially in the context of increasing fluoroquinolone resistance.

Indications for Prostate Biopsy

Prostate biopsy is indicated in several clinical scenarios. An elevated or rising prostate-specific antigen (PSA) level combined with clinical suspicion for prostate cancer warrants biopsy. Abnormal findings on digital rectal examination, such as nodules, induration, or asymmetry, also prompt biopsy. Suspicious lesions identified on MRI, particularly those scored PI-RADS 3 to 5, require tissue sampling. Biopsies are essential for monitoring patients under active surveillance, either as confirmatory or surveillance biopsies. Additionally, elevated biomarkers like the Prostate Health Index (PHI), 4Kscore, or PCA3 that suggest a high risk of aggressive cancer support the decision to biopsy.

Systematic (Template) Biopsy

Technique

The systematic biopsy method involves obtaining 12 cores from the peripheral zone of the prostate in a sextant-plus pattern. Samples are taken bilaterally from the apex, mid-gland, and base, targeting both lateral and medial regions. In repeat biopsy settings, extended templates or saturation biopsies with 20 or more cores may be employed to improve detection. This approach focuses on the peripheral zone, where approximately 70-80% of prostate cancers originate.

Limitations

Despite its widespread use, systematic biopsy has notable limitations. Sampling error can result in missing up to 30% of clinically significant cancers on the initial biopsy. It also tends to overdetect low-grade cancers, particularly Gleason 6, which may lead to overtreatment. Systematic biopsy poorly samples anterior and transition zone lesions, which can harbor significant disease, and has limited ability to detect cancers located at the apex of the prostate.

MRI-Targeted Biopsy

Pre-Biopsy mpMRI

Multiparametric MRI combines T2-weighted imaging, diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps, and dynamic contrast-enhanced (DCE) sequences to characterize prostate lesions. The PI-RADS version 2.1 scoring system categorizes lesions from PI-RADS 1 (very low suspicion) to PI-RADS 5 (very high suspicion). PI-RADS 3 lesions are equivocal, with a 5-30% chance of clinically significant cancer, while PI-RADS 4 and 5 lesions have a 30-60% and greater than 60% likelihood, respectively. The dominant imaging sequence depends on the prostate zone: DWI is most informative for peripheral zone lesions, whereas T2-weighted imaging is preferred for transition zone lesions.

Fusion Approaches

Cognitive Fusion

Cognitive fusion relies on the urologist’s ability to mentally align MRI findings with real-time transrectal ultrasound (TRUS) images during biopsy. This method requires no specialized equipment beyond standard TRUS but is highly operator-dependent. While it is less costly and can be effective for large, obvious PI-RADS 5 lesions, its reproducibility is limited compared to software-assisted methods.

Software (MRI-TRUS) Fusion

Software fusion platforms, such as Artemis, UroNav, and BioJet, co-register pre-biopsy MRI images with real-time TRUS using rigid or elastic registration algorithms. This technology enables precise targeting of MRI-identified lesions, typically obtaining two to four cores per lesion. Software fusion improves reproducibility and allows for accurate tracking of biopsy sites during surveillance.

In-Bore MRI Biopsy

In-bore MRI biopsy is performed within the MRI scanner itself, offering the highest spatial accuracy. However, it is time-consuming, costly, and not widely available. This approach is generally reserved for challenging anterior or apical lesions or cases with prior negative biopsies despite persistent suspicion.

Combined (Targeted + Systematic) vs. Targeted-Only

Clinical trials have compared combined biopsy approaches to targeted-only strategies. The PRECISION trial demonstrated that MRI-targeted biopsy alone detected more clinically significant cancers (38% vs. 26%) than systematic biopsy alone, with fewer detections of low-grade Gleason 6 cancers. The MRI-FIRST trial found that combining targeted and systematic biopsies identified the highest number of significant cancers. The PACIFICO trial showed that targeted biopsy alone was non-inferior to the combined approach for detecting clinically significant disease. Nevertheless, approximately 10-15% of significant cancers are detected only by systematic cores missed by MRI-targeted biopsy alone. Consequently, most guidelines recommend a combined approach for initial biopsies, while targeted-only biopsy may be acceptable for PI-RADS 4-5 lesions at experienced centers. For active surveillance, the combined approach remains standard.

Transrectal vs. Transperineal Approach

Transrectal Ultrasound-Guided Biopsy (TR-Bx)

The traditional transrectal approach involves passing the biopsy needle through the rectal wall under ultrasound guidance. Its advantages include familiarity among clinicians, procedural speed, and the ability to perform under local anesthesia. However, it carries a 2-5% risk of infection despite fluoroquinolone prophylaxis, with rising concerns about fluoroquinolone-resistant organisms such as ESBL-producing E. coli. Other drawbacks include rectal bleeding and difficulty accessing anterior or apical lesions.

Transperineal Biopsy (TP-Bx)

The transperineal approach accesses the prostate through the perineal skin between the scrotum and anus. It can be performed under local anesthesia in an office setting or under general anesthesia. This method offers near-zero sepsis rates (<0.1%) and superior sampling of the anterior prostate and apex. Because it avoids rectal puncture, there is no need for rectal culture-directed prophylaxis, and antibiotic prophylaxis is simplified to a single dose of a cephalosporin. Disadvantages include a higher risk of urinary retention (2-5%), perineal discomfort, and a learning curve for freehand techniques under local anesthesia. Equipment may include coaxial needle guides or freehand methods, with optional use of steppers or grids.

Trend Toward Transperineal

Reflecting concerns about sepsis with the transrectal approach amid increasing antibiotic resistance, the 2023 AUA/SIU best practice statement recommends the transperineal approach when feasible. Office-based transperineal biopsies under local anesthesia are increasingly adopted.

Infection Prophylaxis

Transrectal Biopsy

For transrectal biopsy, targeted antibiotic prophylaxis based on rectal swab cultures is standard, reducing post-biopsy infection rates to below 1%. When rectal swabs are unavailable, augmented prophylaxis combining fluoroquinolones with aminoglycosides may be used. Povidone-iodine rectal preparation is recommended as an adjunct to reduce bacterial load. Risk factors for infection with ESBL-producing organisms include prior fluoroquinolone use, recent hospitalization, international travel, and healthcare worker status.

Transperineal Biopsy

Transperineal biopsy requires only a single dose of a cephalosporin, such as 2 grams of intravenous cefazolin or 500 mg of oral cephalexin. No rectal swab or fluoroquinolone prophylaxis is necessary, and infection rates are dramatically lower, with sepsis occurring in less than 0.1% of cases.

Biopsy Complications

Common complications of prostate biopsy include bleeding, with hematuria occurring in about 50% of patients, hematospermia in 30%, and rectal bleeding in 2-20%, all typically self-limited. Infection and sepsis rates range from 2-5% with transrectal biopsy, especially in the context of fluoroquinolone resistance, but are less than 0.1% with transperineal biopsy. Urinary retention occurs in 1-2% of transrectal and 2-5% of transperineal biopsies. Some patients experience transient erectile dysfunction, with permanent dysfunction being rare. Pain and discomfort are managed with periprostatic nerve block (PPNB) for transrectal biopsies and local perineal block for transperineal biopsies. Vasovagal episodes are more common with the transrectal approach.

Periprostatic Nerve Block (PPNB)

PPNB involves injecting 1% lidocaine at the junction of the prostate and seminal vesicle bilaterally. This technique significantly reduces biopsy-related pain compared to no anesthesia or rectal lidocaine gel alone and is considered the standard of care for transrectal biopsy.

Special Situations

Repeat Biopsy After Prior Negative

Before repeat biopsy, pre-biopsy MRI is strongly recommended to improve detection yield. MRI-targeted biopsy has the highest diagnostic yield in this setting. Saturation biopsy with 20 or more cores via the transperineal approach may be considered for comprehensive sampling. The ConfirmMDx epigenetic assay performed on prior negative tissue can assist in risk stratification.

Active Surveillance Biopsies

Confirmatory biopsy is typically performed within 6 to 12 months of initial diagnosis, with surveillance biopsies repeated every 1 to 2 years depending on protocol. A combined MRI-targeted and systematic biopsy approach is recommended, with software fusion used to track core locations over time.

Anticoagulation Management

Management of anticoagulants around biopsy varies by agent. Aspirin is generally continued despite a minor increase in bleeding risk. Clopidogrel should be held for 5 to 7 days or continued with informed consent regarding bleeding risk. Warfarin is either bridged to low molecular weight heparin or held to achieve an INR below 1.5. Direct oral anticoagulants (DOACs) are typically held for 2 to 3 days before biopsy, with 48 hours for apixaban and rivaroxaban and 72 hours for dabigatran.

<image>A side-by-side comparison illustration of transrectal vs. transperineal prostate biopsy technique. The left panel shows the transrectal approach with the ultrasound probe in the rectum and the biopsy needle passing through the rectal wall into the prostate. The right panel shows the transperineal approach with the ultrasound probe in the rectum for imaging guidance and the biopsy needle entering through the perineal skin. The prostate zones (peripheral, transition, central) are labeled. The 12-core systematic biopsy template is overlaid on one panel, and MRI-targeted cores are shown on the other. Clear anatomic labels with color-coded cores.</image>

<image>An illustration of the MRI-TRUS software fusion biopsy workflow: (1) pre-biopsy MRI with a PI-RADS 4 lesion marked in the right peripheral zone, (2) MRI images loaded into fusion software, (3) real-time TRUS image co-registered with MRI, (4) biopsy needle guided to the fusion target with the tracked trajectory displayed on screen. Side panels show the T2-weighted, DWI, and ADC map MRI sequences. Clean, step-by-step medical technology illustration.</image>

Clinical Pearls

Performing a periprostatic nerve block is essential for transrectal biopsy, as it significantly reduces patient pain and is considered standard care. The transperineal biopsy approach offers near-zero risk of sepsis and is increasingly preferred, especially due to its superior sampling of the anterior prostate. Combining targeted and systematic biopsy cores detects the greatest number of clinically significant cancers, with about 10-15% of significant tumors found only in systematic cores. A negative MRI does not exclude the need for biopsy in men with persistent clinical concern, such as rising PSA or abnormal digital rectal examination, since 5-10% of significant cancers may be invisible on MRI. For transrectal biopsies, rectal culture-directed antibiotic prophylaxis is recommended to reduce fluoroquinolone-resistant infections, whereas transperineal biopsies require only a single-dose cephalosporin. Finally, ensuring the presence of muscularis propria in biopsy specimens is important, as its absence limits accurate staging in bladder cancer and incomplete sampling in prostate biopsy may miss higher-grade cancer components.

References

• Kasivisvanathan V, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION). N Engl J Med. 2018;378(19):1767-1777
• Rouviere O, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST). BMJ. 2019;365:l1890
• Grummet J, et al. Transperineal vs transrectal biopsy for prostate cancer detection: a systematic review and meta-analysis. Eur Urol Focus. 2020;6(4):701-710
• AUA/SIU Best Practice Statement on Transperineal Prostate Biopsy, 2023
• Liss MA, et al. An update of the AUA white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol. 2017;198(2):329-334

Read this lecture as Markdown